Literature DB >> 27645930

Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis.

Santanu Ghosh1, Nabanita Kar1, Tanmoy Bera2.   

Abstract

Oleanolic acid (OA) has low aqueous solubility and low permeability, which results poor bioavailability. To surmount the inadequacy, our aim was to fabricate oleanolic acid loaded poly lactic co- glycolic acid (PLGA)- d-α- tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles, which could be efficacious for the treatment of Leishmania donovani mediated visceral leishmaniasis (VL). OA loaded PLGA- TPGS nanoparticles were prepared by emulsion solvent evaporation technique. Cellular uptake was investigated. In vitro cumulative drug release study was carried out. In vitro susceptibility was confirmed against the amastigotes of Leishmania donovani AG83 wild and drug resistant strains. In vivo antileishmanial activity was evaluated against wild type amastigotes of L. donovani. OA loaded nanoparticles were successfully formulated. The highest drug loading was found to be 11.08%±0.35%. 85.66%±0.56% was the highest in vitro OA release for 30days among the formulations. In vivo study revealed that, 98.82±1.92% amastigote burden in spleen of BALB/c mice were suppressed by the polymeric nanoformulation of OA. Experimental OA nanoparticle formulation proved itself as an attractive carrier for OA which was significantly efficacious against both in vitro and in vivo amastigote form of Leishmania donovani than pure OA for chemotherapeutic intervention of visceral leishmaniasis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  In vivo antileishmanial activity; Oleanolic acid; PLGA nanoparticle

Mesh:

Substances:

Year:  2016        PMID: 27645930     DOI: 10.1016/j.ijbiomac.2016.09.014

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  6 in total

Review 1.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

Review 2.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

Review 3.  Nanostructured delivery systems with improved leishmanicidal activity: a critical review.

Authors:  Natascia Bruni; Barbara Stella; Leonardo Giraudo; Carlo Della Pepa; Daniela Gastaldi; Franco Dosio
Journal:  Int J Nanomedicine       Date:  2017-07-26

4.  Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.

Authors:  Dazhong Chen; Xiaoli Pan; Fangyuan Xie; Ying Lu; Hao Zou; Chuan Yin; Yu Zhang; Jie Gao
Journal:  Int J Nanomedicine       Date:  2018-10-25

Review 5.  Development and Evaluation of Oleanolic Acid Dosage Forms and Its Derivatives.

Authors:  Anjie Feng; Shanjing Yang; Yue Sun; Li Zhang; Fumin Bo; Lingjun Li
Journal:  Biomed Res Int       Date:  2020-11-25       Impact factor: 3.411

6.  RAFT polymerization mediated core-shell supramolecular assembly of PEGMA-co-stearic acid block co-polymer for efficient anticancer drug delivery.

Authors:  Priyatosh Sarkar; Santanu Ghosh; Rima Saha; Kishor Sarkar
Journal:  RSC Adv       Date:  2021-05-07       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.